Search  Website
Survey
FAQs & How to use this site
Home | About Us | Contact Us
Release Archive
News Releases (Archive)
Finasteride saves men from prostate cancer, doesn’t increase risk of death
  [Aug. 14, 2013]
Finasteride saves men from prostate cancer, doesn’t increase risk of death Data from up to 18 years of follow-up of men on the Prostate Cancer Prevention Trial show finasteride reduced the overall risk of a prostate cancer diagnosis by about one-third, raised the risk of a high-grade diagnosis slightly, and had no effect on overall survival times.
 
S0221 finds low-dose weekly paclitaxel as effective as biweekly in early-stage breast cancer
  [Jun. 3, 2013]
S0221 finds low-dose weekly paclitaxel as effective as biweekly in early-stage breast cancer S0221 results show lower dose, weekly regimen of adjuvant paclitaxel (Taxol) chemotherapy for women with early-stage breast cancer was comparable to the standard dose, biweekly regimen, but caused substantially fewer side effects. G. Thomas Budd, M.D., reports the findings today at the American Society for Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago.
 
Landmark SWOG-9346 ADT study results published in New England Journal of Medicine
  [Apr. 3, 2013]
The April 4th NEJM publishes results of phase III SWOG-9346, which found that taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuous androgen-deprivation therapy.
 
Latin America study finds success in H. pylori treatment varies across groups
  [Feb. 12, 2013]
Latin America study finds success in H. pylori treatment varies across groups Gastric cancer, the number two cancer killer globally, often develops as a result of infection with the bacterium Helicobacter pylori, holding out the promise that campaigns to eradicate the bug in high-risk populations could have a significant public health impact. The SWOG S0701 clinical trial, which spanned six Latin American countries, suggests H. pylori eradication campaigns to prevent gastric cancer would need to be narrowly tailored to subpopulations.
 
Four researchers chosen for 2012 SWOG Young Investigators training program
  [Sep. 10, 2012]
Four researchers chosen for 2012 SWOG Young Investigators training program Four of the most promising early career researchers in oncology have been accepted to the 2012 SWOG Young Investigator Training Course, to be held September 10 – 12 in Seattle. This intensive three-day workshop gives early career cancer researchers tools to design and lead large-scale studies across the NCI National Clinical Trials Network.

Left to right:

  • Christopher Lieu, M.D., Assistant Professor, University of Colorado Cancer Center
  • William Lowrance, M.D., M.P.H., Assistant Professor, University of Utah Huntsman Cancer Institute
  • Jatin Shah, M.D., Assistant Professor, MD Anderson Cancer Center
  • William Nassib William, Jr., M.D., Assistant Professor, MD Anderson Cancer Center
 
Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer
  [Aug. 1, 2012]
Anastrozole and fulvestrant combo better than single drug for metastatic breast cancer Results of a SWOG clinical trial published August 2 in the New England Journal of Medicine show the combination of anastrozole and fulvestrant extended the median survival time of women with hormone receptor-positive metastatic breast cancer by more than six months compared to women treated with a standard therapy of anastrozole alone (47.7 months vs 41.3 months).

"The combination offers a new standard for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer," says lead study coordinator Rita Mehta, M.D., of the University of California, Irvine Medical Center.

 
Lower income cancer patients less likely to be involved in clinical trials
  [Jun. 3, 2012]
Lower income cancer patients less likely to be involved in clinical trials Cancer patients with annual household incomes below $50,000 were less likely to participate in clinical trials than patients with annual incomes of $50,000 or higher, and were more likely to be concerned about how to pay for clinical trial participation. This is the conclusion of a large SWOG study presented at the ASCO 2012 meeting by Joseph M. Unger, M.S., Ph.C., of the SWOG Statistical Center and the Fred Hutchinson Cancer Research Center.

The study surveyed 5,499 patients who registered with an online treatment decision tool. In the end, 7.6 percent of survey takers with an annual income below $50,000 reported participating in clinical trials, while 10.0 percent of those with incomes of $50,000 or more said they took part.

 
Intermittent hormone therapy for prostate cancer inferior to continuous therapy
  [Jun. 3, 2012]
Intermittent hormone therapy for prostate cancer inferior to continuous therapy Many men with metastatic, hormone‐sensitive prostate cancer live longer on continuous androgen‐deprivation therapy than on intermittent therapy, according to results of phase III clinical trial SWOG‐9346, the largest such study to date in men with metastatic, hormone‐sensitive disease.

The study’s principal investigator, Maha Hussain, M.D., F.A.C.P., of the University of Michigan Comprehensive Cancer Center, presented the results at the plenary session of the ASCO 2012 meeting in Chicago.

“Based on these results,” Hussain says, “we can conclude that intermittent AD is not as effective as continuous AD in men with metastatic prostate cancer.”

 
Blanke is SWOG chair-elect; LeBlanc is new SWOG group statistician
  [Apr. 14, 2012]
Blanke is SWOG chair-elect; LeBlanc is new SWOG group statistician Charles D. Blanke, M.D., of the British Columbia Cancer Agency and the Univ of BC, is new chair-elect of the SWOG clinical trials cooperative group.

Blanke will serve in that role for one year, becoming group chair when the term of current chair Laurence H. Baker, D.O., expires on May 1 of 2013.

Michael LeBlanc, Ph.D., has been confirmed by SWOG's board of governors as new group statistician for SWOG, replacing John J. Crowley, Ph.D., who had served in the role for 28 years. LeBlanc took over the role April 16, 2012.

 
SWOG S0226 finds anastrozole/fulvestrant combo can extend PFS and OS for ER+ breast cancer patients
  [Dec. 7, 2011]
SWOG S0226 finds anastrozole/fulvestrant combo can extend PFS and OS for ER+ breast cancer patients Post-menopausal women with hormone receptor-positive metastatic breast cancer may have a new treatment option that could lengthen their lives, according to results of SWOG study S0226, presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.

The combination of the two anti-estrogen drugs anastrozole and fulvestrant extended the median survival time of women with breast cancer by more than six months compared to those who underwent standard treatment with anastrozole alone (47.7 months vs 41.3 months). The combination therapy also lengthened the median time to disease progression (15 months vs 13.5 months).

Lead study coordinator Rita Mehta, M.D., of the University of California, Irvine Medical Center says the results of the phase III trial are particularly exciting because “these patients have not had a new treatment that gave them an overall survival benefit in more than a decade.”
 
SWOG SELECT study shows increased prostate cancer risk from vitamin E supplements
  [Oct. 11, 2011]
SWOG SELECT study shows increased prostate cancer risk from vitamin E supplements An updated review of data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded that men who took 400 international units of vitamin E daily had more prostate cancers than men who took a placebo. Results are published in the October 12, 2011, JAMA.

SELECT participants can learn more from the SELECT website.

[Download larger version of graphic.]
 
Four cancer researchers chosen for SWOG’s 2011 Young Investigators workshop
  [Sep. 1, 2011]
Four cancer researchers chosen for SWOG’s 2011 Young Investigators workshop SWOG has selected four talented, early-career researchers for its 2011 Young Investigator Training Course. These four will attend a three-day workshop September 19 – 21 in Seattle, Wash., for intensive training in how to design and conduct cancer clinical trials.
 
3-drug H. pylori regimen superior in Latin America study
  [Jul. 19, 2011]
3-drug <i>H. pylori</i> regimen superior in Latin America study Clinical trials in Europe and Asia were thought to have pinpointed the best treatment regimen to eradicate the H. pylori bug, an important cause of peptic ulcers and gastric cancer. New results from a large SWOG study in Latin America turn those findings on their head, suggesting different populations need different therapies.
 
Group chairs agree to guiding principles for transforming cooperative groups
  [May. 19, 2011]
SWOG has joined with the other cooperative groups in formulating a consensus opinion on upcoming changes to the National Cancer Institute's (NCI's) funding mechanism for clinical trial cooperative groups. We expect that many of the recommendations from the 2010 Institute of Medicine report on the groups will coalesce in the new NCI funding guidelines, and that these guidelines will set the groups' scientific and operational parameters for years to come. The linked public comment is our collective attempt to publicly outline a set of principles we hope will guide the NCI as they move forward.
 
S1007 RxPONDER trial will evaluate whether gene expression test can drive chemotherapy choice
  [Apr. 26, 2011]
S1007 RxPONDER trial will evaluate whether gene expression test can drive chemotherapy choice SWOG-led clinical trial S1007 will recruit 4,000 women to determine whether chemotherapy benefits patients with node positive breast cancer who have low to intermediate Oncotype DX® recurrence scores.
 
S0421 closes early, finds no benefit from atrasentan added to chemo for advanced prostate cancer
  [Apr. 21, 2011]
NCI-supported SWOG trial S0421 has closed early based on interim finding that atrasentan added to docetaxel and prednisone did not confer additional survival benefit to patients with hormone-refractory prostate cancer. Few patients remain on trial medication. Those that do should ask their doctor how to stop safely.
 
Southwest Oncology Group becomes SWOG
  [Apr. 6, 2011]
Noting that the regional focus of it's name no longer fit the national character of the network, the NCI clinical trial cooperative group formerly known as the Southwest Oncology Group announced it will now be simply 'SWOG.'
 
SWOG statement on FDA rejection of finasteride for prostate cancer prevention
  [Dec. 1, 2010]
SWOG has issued a brief statement in response to the FDA Oncologic Drugs Advisory Committee's rejection of the drug finasteride for prostate cancer prevention. SWOG's Prostate Cancer Prevention Trial (PCPT) was the primary source of data in the argument in favor of approving the usage.
 
SWOG statement on FDA review of finasteride
  [Nov. 30, 2010]
SWOG has issued a brief statement concerning the December 1 FDA Oncologic Drugs Advisory Committee review of finasteride for chemoprevention based on results of the Prostate Cancer Prevention Trial.
 
SWOG names 5 cancer researchers as outstanding Young Investigators
  [Sep. 8, 2010]
SWOG names 5 cancer researchers as outstanding Young Investigators SWOG has selected five talented researchers for its 2010 Young Investigators Training Course, an intensive, three-day workshop in how to develop and conduct cancer clinical trials.
 
NCI renews SWOG treatment grants at $120+ million
  [Apr. 9, 2010]
NCI renews SWOG treatment grants at $120+ million The National Cancer Institute's Cancer Therapy Evaluation Program has renewed SWOG's set of treatment grants for a six-year period. SWOG's primary operating grant is projected to be more than $63 million over that time, while the full package of Group-related grants awarded as part of the 2009 competitive renewal process is expected to total more than $120 million.
 
Study confirms breast cancer chemo benefit, but gene test may ID patients not helped
  [Dec. 10, 2009]
Study confirms breast cancer chemo benefit, but gene test may ID patients not helped Chemotherapy added to tamoxifen can improve outcomes for postmenopausal breast cancer patients, according to a landmark study by the Southwest Oncology Group. But a related study finds that a multigene test on tumors can identify a subset of patients who may not benefit from that chemotherapy.
 
$4 million NCI grant funds comparative effectiveness research at Southwest Oncology Group
  [Oct. 15, 2009]
Launched with federal stimulus funds, new CANCERGEN center’s vision is to make Southwest Oncology Group a national leader in cancer comparative effectiveness research.
 

Five chosen for SWOG Young Investigator course

  [Sep. 14, 2009]
<br />Five chosen for SWOG Young Investigator course
Five talented researchers who are early in their career will attend a three-day Southwest Oncology Group workshop for intensive training in how to design and conduct cancer clinical trials.
 
SWOG study sheds light on question of why African-Americans fare worse with cancer
  [Jul. 7, 2009]
An analysis of clinical trial data implicates biological factors behind worse outcomes for African-Americans with breast, ovarian, or prostate cancer.
 
SWOG receives $ 2.5 million to combat stomach cancer
  [Nov. 19, 2008]
Southwest Oncology Group, one of the largest U.S. cancer clinical trial networks, will undertake a clinical trial, supported by a $2,520,905 grant from the Bill & Melinda Gates Foundation to the University of Michigan, to find the most effective way to eradicate an extremely common bacterial infection that is the principal known cause of stomach cancer.
 
Prostate Cancer Prevention Study Shows No Benefit for Use of Selenium and Vitamin E Supplements
  [Oct. 27, 2008]
Prostate Cancer Prevention Study Shows No Benefit for Use of Selenium and Vitamin E Supplements Initial, independent review of study data from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) shows that selenium and vitamin E supplements, taken either alone or together, did not prevent prostate cancer. The data also showed two concerning trends among the over 35,000 men age 50 and older in the trial: small but not statistically significant increases in the number of prostate cancer cases in the men taking only vitamin E and in the number of cases of adult onset diabetes in men taking only selenium. Because this is an early analysis of the data, neither of these findings proves an increased risk from the supplements; both may be due to chance.

News Release

News Release (Spanish)

SELECT Q&A

 
SWOG Renews Focus on Gynecologic Malignancies
  [Apr. 30, 2008]
SWOG Renews Focus on Gynecologic Malignancies SWOG has reactivated its Gynecologic Cancer Committee with a $250,000 grant from the Marsha Rivkin Center for Ovarian Cancer Research. This one-time grant to the Hope Foundation, the philanthropic arm of SWOG, will defer the expense associated with the start-up of this committee, including costs associated with coordination of education and research initiatives. See the press release.
 
New Finasteride Findings from PCPT
  [Oct. 1, 2007]
A newly published PCPT follow-up study, along with two others published recently, strongly suggests that finasteride makes it easier for physicians to detect high-grade cancers early by improving screening tests and prostate biopsy itself. This casts further light on an initially puzzling finding of PCPT: Men who took finasteride but still developed prostate cancer by the end of that study had higher rates of detected high-grade tumors than did men in the placebo group. News Release.
 
2007 Young Investigators Selected
  [Sep. 1, 2007]
Four talented young investigators were chosen after a rigorous and competitive application process to participate in The “Young Investigators” Training Course this Fall. The course includes intensive study of statistical principles, data collection and analysis, critical decision-making, protocol development and Southwest Oncology Group procedures to learn how to design a clinical trial.
 
S9921 Closed
  [Jan. 22, 2007]
S9921, a Southwest Oncology Group study entitled "Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III," has been closed because of safety concerns. For details, see the news release.
 
Prostate Cancer RT Treatment Outcomes Analyzed
  [Jan. 17, 2007]
Results of a SWOG study show that radiotherapy given to locally advanced prostate cancer patients after prostatectomy does not significantly reduce the risk of subsequent cancer spread to distant sites, but does significantly lower the risk of local cancer recurrence compared to men who do not receive radiation. News Release
 
Young Investigators Complete Training
  [Sep. 30, 2006]
Six talented cancer researchers, chosen through a competitive process, completed the Southwest Oncology Group Young Investigators Training Course in September. The course puts the physicians on a fast track to develop and conduct cancer clinical trials through the Southwest Oncology Group. Press Release contains details.
 
Innovative Prognostic Indicator Breast Trial
  [Sep. 1, 2006]
Newly-opened Southwest Oncology Group study S0500 will seek to find out whether circulating tumor cells can be used to predict which women with metastatic breast cancer are responding well to a particular treatment and which are not. Early identification of those not responding to treatment will allow for more timely consideration of other treatment options. News Release
 
Young Investigators Complete Training
  [Sep. 22, 2005]
Young Investigators Complete Training Four talented cancer researchers, chosen through a competitive process, just completed the Southwest Oncology Group Young Investigators Training Course. The course puts the physicians on a fast track to develop and conduct cancer clinical trials through the Southwest Oncology Group. Press Release contains details. Photo
 
PSA's Validity as a Screening Test Evaluated
  [Jul. 11, 2005]
PSA's Validity as a Screening Test Evaluated A new data analysis from the Prostate Cancer Prevention Trial shows that Prostate-Specific Antigen is frequently inaccurate in testing for prostate cancer risk. Read more about it in the press release and the abstract. The data analysis was led by PCPT Study Coordinator Ian M. Thompson, Jr., M.D.
 
S0023 Closed
  [Apr. 18, 2005]
The National Cancer Institute issued a press release on April 18, 2005 announcing the closure of Southwest Oncology Group study S0023. This is a randomized trial for patients with locally advanced non-small cell lung cancer comparing gefitinib (Iressa™) versus a placebo following chemotherapy and radiation. A review of interim data has indicated that gefitinib would not improve survival. Detailed results from the study will be presented at the American Society of Clinical Oncology annual meeting May 13-17.
 
News Releases 
 
SWOG in the News (Archive)
New U Tenn SWOG affiliate cited
  [Sep. 28, 2009]
The Cookeville Times of Tennessee recognized the Cookeville Regional Cancer Center for its recent affiliation with SWOG through the University of Tennessee Health Care System.
 
IASLC: Four-Drug Therapy for NSCLC Appears Well Tolerated
  [Aug. 3, 2009]
MedPage Today reported on a presentation by Edward Kim, M.D., of M.D. Anderson Cancer Center, to the world conference of the International Association for the Study of Lung Cancer (IASLC) in San Francisco. Kim presented an abstract on the the results of S0536, a SWOG phase II study on the feasibility of using a four-drug regimen that includes cetuximab in the treatment of advanced non-small cell lung cancer. SWOG study S0819 has just been activated based in part on the S0536 results Kim reported on.
 
JNCI paper on SWOG racial disparities study resonates in the media
  [Jul. 7, 2009]
<i>JNCI</i> paper on SWOG racial disparities study resonates in the media Media venues from the Washington Post to Voice of America found something to report on in a SWOG study on the sources of racial disparities in cancer outcomes. SWOG investigators quoted include Kathy Albain, M.D., Joe Unger, M.S., Dawn Hershman, M.D., Ph.D., and Frank Meyskens, M.D.

Below is a selection of media outlets that covered the study, with links to their stories. You can also read the SWOG press release on the study.
 
Center for Science in the Public Interest sues Bayer for ignoring SELECT
  [Jun. 18, 2009]
Center for Science in the Public Interest sues Bayer for ignoring SELECT Do selenium and vitamin E prevent prostate cancer? The SELECT trial put that claim to rest last year, but Bayer apparently still makes advertising claims that the selenium in its supplements will help men prevent prostate cancer. Today the Center for Science in the Public Interest threatened to sue Bayer if they don't stop making such claims. The WalletPop Web site reports.
 
SWOG 9912 abstract at ASCO covered in UroToday
  [Jun. 1, 2009]
An abstract on SWOG study S9921, presented at the annual ASCO meeting this past weekend in Orlando, has been covered in today's edition of UroToday.

The abstract, which was presented orally on Saturday by lead author L.M. Gode, MD, reported on benefits of hormonal therapy to high-risk prostate cancer patients.

You can read the full abstract, "Southwest Oncology Group S9921: Prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation," on the ASCO Web site.
 
SWOG's Dr. Brian G.M. Durie, MD, quoted in Modern Medicine
  [May. 29, 2009]
Dr. Brian G.M. Durie, vice-chair of SWOG's Myeloma Committee, is quoted in an article in Modern Medicine commenting on proposed federal legislation that would mandate that insurance plans cover oral and intravenous cancer drugs equally.

Durie says oncologists need the freedom to choose therapies based upon their potential efficacy rather than " inequitable and irrational differences in reimbursement."
 
SWOG's Dr. Julie R. Gralow, MD, featured on The Group Room radio show from ASCO 2009
  [May. 28, 2009]
This weekend's broadcast of The Group Room, a weekly call-in radio show on cancer, will feature SWOG's own Dr. Julie R. Gralow, MD, vice-chair of SWOG's Breast Cancer Committee, live from the ASCO conference in Orlando.

The Sunday, May 31st show runs from 4-6:00 p.m. EDT and will also be videocast live at www.vitaloptions.org and available as a podcast on iTunes.
 
NCI Bulletin reports on SWOG follow-up showing benefits of radiation after prostate surgery
  [May. 20, 2009]
NCI Bulletin reports on SWOG follow-up showing benefits of radiation after prostate surgery The May 19, 2009 issue of the National Cancer Institute Bulletin reports on a follow-up to a SWOG study (S8794) that shows that radiation therapy after surgery delays recurrence and prolongs life for men whose cancer had spread beyond the prostate. Read "Decades Later, Seeing the Benefits of Radiation after Prostate Surgery."

The results the NCI Bulletin reports on appeared in the March 2009 issue of the Journal of Urology. Dr. Ian N. Thompson of the University of Texas Health Science Center at San Antonio was lead author.
 
SWOG at ASCO 2009
  [May. 19, 2009]
SWOG at ASCO 2009
Southwest Oncology Group studies have resulted in 17 abstracts at this year's annual meeting of the American Society of Clinical Oncology. View the listing of SWOG abstracts online, or download a PDF version to print and take with you.
 
NCI-Sponsored Cancer Trials Offer Decent Clinical Return on Investment
  [Mar. 24, 2008]
MedPage Today reported on a study by Dr. Benjamin Djulbegovic, et.al., which showed that clinical trials conducted by the National Cancer Institute's Cooperative Groups, including SWOG, were beneficial in driving therapeutic advances in clinical medicine.
 
Prostate Cancer RT Treatment Outcomes Analyzed
  [Sep. 1, 2007]
Results of a SWOG study show that radiotherapy given to locally advanced prostate cancer patients after prostatectomy does not significantly reduce the risk of subsequent cancer spread to distant sites, but does significantly lower the risk of local cancer recurrence compared to men who do not receive radiation.
 
SWOG Chair receives Sarcoma Foundation Award
  [May. 22, 2006]
On May 22, SWOG Chairman Laurence H. Baker, D.O., was presented the Sarcoma Foundation of America’s Nobility in Science Award for his 34-year commitment to the advancement of scientific knowledge about sarcoma. News Release
 
New Standard Treatment for Advanced Ovarian Cancer
  [Jan. 6, 2006]
NCI released a clinical announcement on January 5, 2006, concerning recommended treatment for advanced ovarian cancer. Southwest Oncology Group trials helped solidify evidence for this recommendation. Read the SWOG news release here concerning the Group's participation in the science that led to this announcement. Based on the results of eight phase III clinical trials, including SWOG-8501 and GOG-114 (SWOG-9227), NCI is encouraging doctors to follow surgery with a combination of two drug-delivery methods: intravenous and intraperitoneal. The combined approach, though more toxic, extends overall survival for women with advanced ovarian cancer by about a year compared to intravenous delivery alone.
 
SWOG in the News 
 
 
     
SWOG Logo Disclaimer | Copyright ©2000-2014 SWOG. All rights reserved.
Design by nuMedia Group Inc. | Hosting by WorldPost Technologies, Inc.
SWOG is FISMA CertifiedSWOG is FISMA Certified